Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Teleflex Inc.

www.teleflex.com

Latest From Teleflex Inc.

Global Device Approvals, Weekly Snapshot: Teleflex, Abiomed Gain Cardio Approvals

A snapshot of global device approvals captured during the past week in Medtech Insight's Approvals Tracker. This week, Teleflex's recently acquired Essential Medical business gained US approval for a closely watched vascular closure device and Abiomed gained a CE mark for a remote monitoring technology.

MTI 100: Major M&A Bookends Year Of Mainly Steady Growth For Leading Medtech Groups

In Medtech Insight's latest rankings of top 100 revenue-earners in the medical device and diagnostics sector, it was steady as she goes for most of the multinational medtechs, with some major exceptions. But there will be more M&A reflected in next year's ranking based on 2018 revenues. Also, medtech groups leading the global market tightened their grip further in 2017, as providers chose to partner more and more with fewer suppliers who can offer a wider provision of services.

Commercial M & A

Avanos/Halyard Tops Recent Medtech CEO-To-Worker Pay Ratio Disclosures

While most device companies filing 2017 annual reports in the first half of 2018 showed CEO-to-worker pay ratios averaging 219:1, Halyard Health (recently renamed Avanos Medical) CEO Joseph F. Woody was compensated 1,250 times what the company’s median employee earned, according to recent disclosures. Medtech Insight also examined CEO-to-worker pay ratios at Align Technologies, Abbott Laboratories, Danaher and Bio-Rad Laboratories, among other firms.

Leadership Companies

Device/Diagnostics Quarterly Deal-Making Statistics, Q4 2017

Device fundraising during the fourth quarter totaled $2.6 billion, making it the strongest quarter of the year. Q4 M&A activity reached $3.9 billion, higher than Q3's $3.4 billion, but still one of the lowest quarters of the year. Both fourth quarter diagnostics financings and M&As hit an all-year low of $622 million, and $2.8 million, respectively.

Deals Market Intelligence
See All

Company Information

UsernamePublicRestriction

Register